Samsung Biologics has announced its intent to acquire PolyPeptide Group, a leading contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs), through an all-cash public tender offer valued at SFr1.46 billion (approximately $1.81 billion). This strategic move signifies Samsung Biologics’ ambition to significantly broaden its service portfolio beyond its established expertise in antibody-based biologics and antibody-drug conjugates (ADCs), tapping into the rapidly expanding market for peptide therapeutics. The transaction, expected to be completed by the end of 2026, positions Samsung Biologics as a more comprehensive CDMO, catering to a wider spectrum of drug modalities and enhancing its global operational footprint.
Strategic Rationale and Market Expansion
The acquisition of PolyPeptide Group is driven by Samsung Biologics’ long-term growth strategy, which emphasizes modality diversification and increased geographic reach. The company aims to leverage PolyPeptide’s deep expertise in peptide synthesis, a complex and increasingly important area of pharmaceutical development, particularly for therapeutic peptides like glucagon-like peptide-1 (GLP-1) receptor agonists, which have seen remarkable success in treating diabetes and obesity.
"This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach and proximity further within the US, Europe, and India," stated John Rim, CEO and Chairman of Samsung Biologics. "We highly value PolyPeptide’s world-class employees, industry-leading capabilities, and global operational footprint, and look forward to leveraging the complementary strengths of PolyPeptide and Samsung Biologics in our continued growth supporting clients as the CDMO of choice for decades to come."
The global peptide therapeutics market is experiencing robust growth, projected to reach over $60 billion by 2027, driven by the increasing prevalence of chronic diseases and advancements in peptide synthesis and delivery technologies. PolyPeptide, with its extensive history of producing over 1,000 therapeutic peptides and its established manufacturing sites across Europe, India, and the United States, is an ideal partner for Samsung Biologics to capture a significant share of this burgeoning market.
Transaction Details and Anticipated Timeline
The proposed offer is set at SFr44.31 per share for 100% of PolyPeptide’s fully diluted share capital, excluding treasury shares. This price represents a 40% premium to PolyPeptide’s last undisturbed share price as of April 10, 2026, and approximately an 11.6% premium to the 60-day volume-weighted average price, reflecting a strong valuation for the target company.
The completion of the deal is contingent upon several key factors, including a minimum acceptance threshold of nearly 67% of PolyPeptide’s shares, the securing of all necessary regulatory approvals, and the fulfillment of other conditions stipulated under Swiss takeover law. Samsung Biologics anticipates the transaction to be finalized by the end of 2026.
Board Recommendation and Shareholder Support
PolyPeptide Group’s board of directors, acting through its independent and non-conflicted members, has unanimously recommended that shareholders accept the tender offer. This recommendation is subject to the terms and conditions that will be detailed in the forthcoming prospectus.
Further solidifying the support for the acquisition, PolyPeptide’s largest shareholder, which holds approximately 55.65% of the outstanding shares (excluding treasury shares), has provided an irrevocable undertaking to tender its shares into the offer. This significant commitment substantially de-risks the transaction and signals strong confidence in the strategic direction and financial benefits of the proposed acquisition.
PolyPeptide Group: A Leader in Peptide Manufacturing
Founded with a focus on peptide-based APIs, PolyPeptide Group has established itself as a global leader in its field. The company operates state-of-the-art facilities strategically located in Belgium, France, India, Sweden, and the United States, complemented by a corporate office in Switzerland and an Innovation Centre in France. This extensive network provides a robust foundation for global peptide manufacturing and development services.
Over its history, PolyPeptide has cultivated deep scientific expertise and advanced manufacturing capabilities, enabling the production of complex therapeutic peptides for a diverse range of therapeutic areas. Its commitment to innovation and quality has made it a trusted partner for pharmaceutical and biotechnology companies worldwide.
Implications for Samsung Biologics and the CDMO Landscape
The acquisition of PolyPeptide represents a significant strategic pivot for Samsung Biologics, moving beyond its core strength in biologics to encompass small molecule and peptide manufacturing. This diversification is crucial in an increasingly complex pharmaceutical development landscape where clients often seek integrated solutions across multiple modalities.
By adding peptide capabilities, Samsung Biologics can now offer a more comprehensive suite of services, from antibody-based drugs to small molecules and peptides. This integrated approach can streamline drug development processes for clients, potentially reducing timelines and costs. The expanded geographic footprint also enhances Samsung Biologics’ ability to serve a global client base more effectively, offering localized manufacturing and support in key markets.
The move also signals a broader trend within the CDMO sector, where companies are increasingly looking to specialize and consolidate to gain competitive advantages. Samsung Biologics’ acquisition of a specialized peptide manufacturer like PolyPeptide is a clear indication of this strategy.
Financial Advisors and Legal Counsel
Samsung Biologics has engaged JP Morgan as its exclusive financial adviser for this transaction. Ernst & Young Han Young is serving as the accounting and tax adviser. Legal counsel is being provided by O’Melveny & Myers and Schellenberg Wittmer. This team of experienced advisors underscores the significance and complexity of the proposed acquisition.
Broader Context: Samsung Biologics’ Growth Trajectory
This acquisition follows a period of substantial growth and strategic expansion for Samsung Biologics. The company has been actively investing in expanding its manufacturing capacity and technological capabilities, solidifying its position as one of the world’s leading biologics CDMOs. Recent initiatives include collaborations aimed at enhancing global vaccine production preparedness, such as the partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) for an outbreak-ready vaccine manufacturing initiative.
The acquisition of PolyPeptide is a natural extension of this growth trajectory, demonstrating Samsung Biologics’ commitment to becoming a one-stop shop for pharmaceutical manufacturing solutions. By diversifying its service offerings, the company aims to mitigate risks associated with reliance on a single modality and capitalize on emerging opportunities in various therapeutic areas.
Future Outlook and Integration Challenges
Upon successful completion of the tender offer and subsequent acquisition of all remaining shares, Samsung Biologics plans to delist PolyPeptide from the SIX Swiss Exchange. The integration of PolyPeptide’s operations, employees, and technologies into Samsung Biologics’ existing structure will be a critical factor in realizing the full strategic and financial benefits of the deal.
Key considerations for integration will include harmonizing operational processes, maintaining PolyPeptide’s high standards of quality and regulatory compliance, and fostering a cohesive corporate culture. However, given the complementary nature of the businesses and the strong recommendation from PolyPeptide’s board, the integration is anticipated to be a smooth process, paving the way for enhanced growth and innovation in the peptide therapeutics market.
The acquisition of PolyPeptide Group by Samsung Biologics marks a significant development in the CDMO industry, signaling a strategic expansion into peptide therapeutics and reinforcing Samsung Biologics’ commitment to providing comprehensive drug development and manufacturing solutions to its global clientele. The deal is poised to reshape the competitive landscape, offering clients a more integrated and versatile partner for their evolving pharmaceutical needs.
